75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 ...
Study data also showed prolonged progression-free survival with 177 Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich ...
NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...
SAN DIEGO, March 17, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, ...
And how many of them are needed to build a house of cards? Just one — if you're willing to decorate it with decimals and call it science. A global analysis claims plastics are responsible for 13.497% ...
The MarketWatch News Department was not involved in the creation of this content. -- Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback